Report Highlights

India Urinary Catheters: Market Overview

India's urinary catheter market is valued at USD 412.6 million in 2024, structured across three primary product tiers: indwelling Foley catheters commanding the largest volume share, intermittent catheters growing rapidly through home care adoption, and external catheters serving a nascent but expanding male continence segment. The market is overwhelmingly hospital-driven, with government procurement through Central and State Medical Services Societies accounting for the majority of unit volumes. Private hospital networks such as Apollo Hospitals and Fortis Healthcare represent a premium pricing tier, while Tier 2 and Tier 3 city facilities typically purchase through state government frameworks at controlled rates.

Government policy has been the dominant force shaping current market structure. The National Medical Devices Policy 2023, approved by the Union Cabinet in April 2023, designated urinary catheters as an essential medical device category, subjecting them to Bureau of Indian Standards (BIS) mandatory certification under the Medical Devices Rules 2017 (amended 2020). This regulatory architecture has consolidated the supplier base around companies capable of sustaining dual BIS and ISO 13485 compliance, effectively raising entry barriers for smaller domestic manufacturers while favouring established multinational and large Indian producers. The private sector has led in product innovation, particularly in anti-infective and hydrophilic-coated catheter variants, but volume remains anchored by government purchasing decisions.

Policy-Driven Growth in Urinary Catheters in India

Three specific policy mechanisms are generating measurable market growth. First, the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) health insurance scheme, covering over 550 million beneficiaries, includes urological procedures and post-operative catheterisation under its Health Benefit Package (HBP) 2022 revision. The HBP 2022 explicitly lists urinary catheterisation consumables as reimbursable, directly expanding institutional demand from empanelled hospitals. The National Health Authority reported 30 million-plus AB-PMJAY hospitalisations annually by 2023, each carrying catheter utilisation probability in surgical and critical care contexts.

Second, the Production Linked Incentive (PLI) Scheme for Medical Devices, administered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, offers 5% financial incentive on incremental sales for domestically manufactured catheters under the "disposable medical devices" subcategory. Third, the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) programme is funding the establishment of 22 new AIIMS-type institutions and upgrading 75 government medical colleges, each representing a captive procurement node with annual catheter budgets exceeding INR 5–10 crore per facility. Collectively, these three mechanisms directly translate into an estimated 12–15% annual volume increase in government procurement channels through 2028.

Regulatory Barriers and Compliance Costs

The Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare, is the primary licensing authority for urinary catheters in India under the Medical Devices Rules 2017. Manufacturers or importers must obtain a Manufacturing Licence (Form MD-5) or Import Licence (Form MD-14) respectively, a process that typically requires 90–180 days for new applicants and involves technical dossier submission, factory inspection by State Licensing Authorities, and BIS certification under IS 7864 for latex catheters. The compliance cost burden for a mid-sized domestic manufacturer registering a new catheter line is estimated at INR 15–25 lakh in direct regulatory expenditure, excluding manufacturing upgrades required to meet IS/ISO standards.

Local content rules present a second significant barrier. The Public Procurement (Preference to Make in India) Order 2017, revised in 2020, mandates that government tenders above INR 200 crore prefer domestically manufactured devices — but the definition of "domestic manufacture" requires minimum 50% local value addition, which most catheter assemblers who import raw latex, silicone, or hydrophilic coating materials from China and Germany currently cannot meet. Price controls under the National Pharmaceutical Pricing Authority (NPPA) do not yet extend directly to urinary catheters, but CMSS tender prices function as effective price ceilings, compressing margins on standard Foley catheters to 8–12% gross margins for suppliers, making premium coating technology difficult to recoup financially in the public channel.

Policy-Created Opportunities in India

The most immediate policy-created opportunity lies in the Ayushman Bharat Digital Mission (ABDM) integration with home care reimbursement. The Ministry of Health and Family Welfare's 2023 guidelines on Home-Based Healthcare explicitly include urological catheter management as a reimbursable home care service for post-surgical and neurological patients. This creates a structured demand channel for intermittent catheter kits outside hospitals — a segment currently worth less than 8% of market value but projected to reach 20% by 2030 as ABDM-linked claims processing matures. Companies that establish dedicated home care catheter product lines and distribution partnerships with ABDM-registered home health providers gain first-mover procurement preference.

A second significant opportunity arises from the Medical Devices Park scheme, under which the Ministry of Chemicals and Fertilizers is funding four dedicated medical device manufacturing parks in Andhra Pradesh (Sri City), Tamil Nadu, Himachal Pradesh, and Uttar Pradesh, with capital subsidy of 30% on project cost up to INR 150 crore per park tenant. Catheter manufacturers establishing production units within these parks gain PLI incentives, subsidised infrastructure, and proximity to state government procurement networks simultaneously. A third emerging opportunity is the Central Government Health Scheme (CGHS) rate revision anticipated in 2025, which is expected to include hydrophilic intermittent catheters for neurogenic bladder patients — a category currently outside CGHS coverage — directly opening a new reimbursed demand segment estimated at 2.5 million units annually.

Market at a Glance

Leading Market Participants

• B. Braun Medical India Pvt. Ltd.
• Becton Dickinson India Pvt. Ltd.
• Coloplast India Pvt. Ltd.
• Teleflex India Pvt. Ltd.
• Medline Industries India
• Romsons Scientific and Surgical Industries
• Hindustan Syringes and Medical Devices Ltd.
• Sterimed Medical Devices Pvt. Ltd.
• Angiplast Pvt. Ltd.
• Bard Medical (India) — a BD company

Regulatory and Policy Environment

The primary legislative framework governing urinary catheters in India is the Medical Devices Rules 2017, notified under the Drugs and Cosmetics Act 1940 (as amended), with CDSCO as the central regulatory authority. Urinary catheters are classified as Class B medical devices under Schedule III of the Medical Devices Rules, requiring State Licensing Authority approval for manufacturing and CDSCO approval for import. BIS mandatory certification under IS 7864:2005 (Specification for Urinary Catheters) applies to all latex variants sold in India, administered by the Bureau of Indian Standards under the Ministry of Consumer Affairs. A significant upcoming change is the planned extension of mandatory CDSCO registration to all Class A and Class B devices by December 2025 under the Medical Devices (Amendment) Rules 2020 phased implementation schedule, which will require all currently exempted small domestic catheter producers to obtain full regulatory approval or exit the market.

Compared to regional peers, India's regulatory framework is more centralised than Indonesia's (which relies on BPOM with looser device-specific standards) but less mature than China's NMPA framework, which mandates post-market surveillance reports annually for Class II devices — a requirement India is expected to introduce in the Medical Devices (Post Market Surveillance) Rules anticipated by 2026. The Quality Council of India's National Accreditation Board for Certification Bodies (NABCB) is expanding the pool of ISO 13485 certification bodies operating in India, which is expected to reduce certification timelines from the current 12–18 months to 8–10 months by 2026, lowering compliance barriers for domestic entrants. Companies should note that the CMSS tender qualification process now cross-references CDSCO registration status in real time, meaning lapses in registration renewal directly translate to tender disqualification.

Long-Term Policy Outlook for India's Urinary Catheter Market

By 2032, three policy trajectories will materially reshape this market. The National Health Policy 2017's successor framework, expected to be notified between 2026 and 2028, is anticipated to formalise Universal Health Coverage targets that extend AB-PMJAY benefits to the remaining uninsured population — adding an estimated 200 million additional beneficiaries and proportionally expanding the reimbursed catheterisation episode base. Simultaneously, CDSCO's phased implementation of Unique Device Identification (UDI) requirements — already mandatory for Class C and D devices since 2023 — will extend to Class B devices including urinary catheters by 2027, requiring manufacturers to embed UDI codes and register devices in the national database, adding traceability infrastructure costs but also creating procurement transparency that disadvantages uncertified imports.

The Make in India initiative's medical devices component, specifically the National Medical Devices Policy 2023 target of achieving 70% domestic production by 2047, will drive increasing preference for local manufacturers in government procurement by 2030. Policy amendments to the Public Procurement Order are expected to tighten local value addition requirements from 50% to 65% by 2028, forcing multinational companies to either deepen India manufacturing or risk progressive exclusion from the dominant government procurement channel. The combination of UDI mandates, tighter local content rules, and expanded insurance coverage will reward manufacturers who invest in India-based production, regulatory infrastructure, and home care distribution networks over the 2025–2032 forecast horizon.